Klothea Bio
Miami, US · Founded 2024 · Delaware corporation
Find your way into Klothea Bio
588 people in our graph share verified history with the Klothea Bio team — schools, employers, funds. One of them is your warm intro.
Ian Marshunlockedknows Olivier Jarry · together at HEC Paris (overlapped)
×5knows the team · via The London School of Economics and Political Science (LSE)
knows the team · via HEC Paris
×2knows the team · via Bayer HealthCare
×2knows the team · via TRIUM Global Executive MBA
knows the team · via DarioHealth
Klothea develops mRNA-based therapeutics designed to trigger adjustable and reversible secretion of the Klotho protein, aiming to address the protein deficit linked to age-related diseases. The company uses proprietary mRNA and safe nanocarriers intended for repeated use, and is also evaluating delivery methods such as extracellular vesicles (exosomes).
Founders & leadership
JB
Jeffrey B. MaddeninCo-Founder and Executive Chairman
OJ
Olivier JarryinChief Operating OfficerOlivier Jarry has spent over three decades in healthcare and business leadership across Europe, the Americas, and Asia, with experience in P&L management, M&A transactions, and capital raising for biotech and medtech companies. He holds advisory and board positions at multiple investment and healthcare-focused organizations.
AF
Agustin Fernandez Santana IIINamed on SEC filing
Board
PS
Petr SramekBoard director
WS
Walter SchmidtBoard director
Reported raises · per SEC filings
Form D private placements$6.9M disclosed across 1 round · 2024
▶$6.9MraisedSep 2026 · 22 investors · Other Health CareRule 506(b)
▶$6.9MraisedSep 2026 · 22 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- Jeffrey B. MaddenExecutive Officer, Director
- Agustin Fernandez Santana IIIExecutive Officer, Director
- Olivier JarryExecutive Officer
- Walter SchmidtDirector
- Petr SramekDirector
- Offering amount
- $10.4M
- Amount sold
- $6.9M
- Sales commissions
- $12.5K
- Placement agents
- Finalis Securities, LLC
- First sale
- Oct 2024
- Incorporated
- Corporation, Delaware, 2024
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
In the news
Frequently asked questions
- What does Klothea Bio do?
- Klothea develops mRNA-based therapeutics designed to trigger adjustable and reversible secretion of the Klotho protein, aiming to address the protein deficit linked to age-related diseases. The company uses proprietary mRNA and safe nanocarriers intended for repeated use, and is also evaluating delivery methods such as extracellular vesicles (exosomes).
- How much funding has Klothea Bio raised?
- Klothea Bio has disclosed $6.9M raised across 1 round.
- Where is Klothea Bio headquartered?
- Klothea Bio is headquartered in Miami, US.